Inaxaplin (VX-147): A First-in-Class Therapy Targeting APOL1-Mediated Kidney Disease
Chronic kidney disease (CKD) remains a significant global health challenge, particularly among individuals with African ancestry. A notable contributor to this disparity is the presence of high-risk variants in the APOL1 gene, which are associated with an increased risk of kidney diseases such as focal segmental glomerulosclerosis (FSGS) and HIV-associated nephropathy. Addressing this unmet medical need, Inaxaplin (VX-147), developed by Vertex Pharmaceuticals, emerges as a promising first-in-class oral therapy specifically targeting APOL1-mediated kidney disease (AMKD).
Written by Zayra Otero, 07/07/25